Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone Sells 7,080 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jazz Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ JAZZ opened at $138.81 on Friday. The company has a 50 day simple moving average of $128.14 and a 200-day simple moving average of $120.00. The company has a market capitalization of $8.43 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on JAZZ shares. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Royal Bank of Canada reduced their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Barclays reiterated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $189.40.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. CWA Asset Management Group LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the period. Centre Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $464,000. Finally, Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.